How Drugmakers Are Using Real-World Data to Accelerate Market Access

Data technology background. Big data visualization. Flow of data. Information code. Background in a matrix style. 4k rendering.

Market access for therapeutics requires extensive data to plan for regulatory compliance, reimbursement, and successful rollout. Drug manufacturers are increasingly relying on real-world data (RWD) like claims data, electronic health records (EHR), and clinical lab data, for this process, gleaning insights about patient journeys, barriers to access, and prescriber preferences.

According to Dinish Kabaleeswaran, “By analyzing claims and coverage data in parallel, manufacturers can arrive at a deeper understanding of the patient journey—and determine how to intervene. For example, when a patient is moving from a first-line to a second-line therapy, what’s influencing this shift? Is the change patient-driven, a result of side effects? Or is it driven by physicians or payers? In an MMIT analysis of oncology categories, we found that a considerable percentage of therapy changes are influenced by payers.”

To read more, click here.

(Source: BioPharma Dive, May 15^th, 2023)